Clinical trial
The Safety and Efficacy of DaxibotulinumtoxinA-Lanm for Benign Essential Blepharospasm and Hemifacial Spasm
NCT06195241 is registered in ClinicalTrials.gov with Montefiore Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Safety and Efficacy of DaxibotulinumtoxinA-Lanm for Benign Essential Blepharospasm and Hemifacial Spasm
- Lead sponsor
- Montefiore Medical Center
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- February 11, 2025
- Completion date
- March 31, 2027
- Enrollment
- 40 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
benign essential blepharospasm, hemifacial spasm